BioNxt Solutions Inc. (FRA:BXT)

Market Cap	51.16M
Revenue (ttm)	14.71K
Net Income (ttm)	-3.68M
Shares Out	n/a
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,705
Average Volume	48,408
Open	0.4020
Previous Close	0.4290
Day's Range	0.4020 - 0.4480
52-Week Range	0.1200 - 0.4430
Beta	n/a
RSI	68.27
Earnings Date	Aug 27, 2025

About BioNxt Solutions

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; and BNT24004 for the treatment of semaglutide. It also offers diagnostic screening tests; new a...

• Industry: Pharmaceutical Preparations
• Founded: 2017
• Country: Canada
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BXT

Financial Performance

In 2024, BioNxt Solutions's revenue was 26,985, a decrease of -92.75% compared to the previous year's 372,247. Losses were -5.31 million, -31.22% less than in 2023.

Financial numbers in CAD